Feipeng Xu | Colon Cancer | Industry Impact Award

Published on by Oncology

 

Industry Impact Award

Feipeng Xu
Hospital of Guangdong Medical University
Researcher Information
Affiliation Hospital of Guangdong Medical University
Country China
Scopus ID 6602700632
Documents 20
Citations
100
h-index 6
Subject Area Colon Cancer
Event International Research Awards on Oncology and Cancer Research
ORCID 0000-0001-9927-6354

The Industry Impact Award recognizes scholarly excellence and measurable contributions to translational oncology and cancer research. Feipeng Xu of the Hospital of Guangdong Medical University has been associated with multiple scientific investigations in the field of colon cancer research, including studies focused on tumor progression, clinical prognosis, therapeutic biomarkers, and molecular oncology.[1] The recognition highlights sustained academic productivity, interdisciplinary collaboration, and contributions to evidence-based cancer science within international research communities.[2]

Abstract

The Industry Impact Award article documents the academic and scientific profile of Feipeng Xu, a researcher affiliated with the Hospital of Guangdong Medical University. The recognition is associated with contributions to colon cancer research, molecular oncology, and translational clinical investigations. The article summarizes the researcher’s scholarly activities, publication history, citation metrics, and broader impact on oncology-related scientific literature.[1] Particular emphasis is placed on interdisciplinary cancer studies, biomarker identification, and research dissemination through indexed scientific platforms.[3]

Keywords

  • Colon Cancer
  • Molecular Oncology
  • Cancer Biomarkers
  • Clinical Research
  • Translational Medicine
  • Oncology Research Awards

Introduction

Colon cancer remains one of the leading causes of cancer-related morbidity and mortality worldwide, necessitating continued advancements in early diagnosis, molecular characterization, and therapeutic innovation.[4] Researchers contributing to translational oncology frequently engage in multidisciplinary collaborations that integrate pathology, genomics, clinical oncology, and therapeutic evaluation. Feipeng Xu has participated in academic research activities that align with these scientific priorities, particularly in relation to gastrointestinal malignancies and clinical oncology investigations.[2]

Recognition through international oncology award programs is generally associated with publication quality, citation performance, collaborative influence, and contribution to evidence-based medicine. The Industry Impact Award reflects these academic indicators and acknowledges sustained involvement in oncology-related scholarly output.[5]

Research Profile

Feipeng Xu is affiliated with the Hospital of Guangdong Medical University in China and has contributed to oncology-focused scientific literature indexed through major academic databases.[1] The researcher’s publication profile demonstrates involvement in cancer biology, molecular diagnostics, tumor progression studies, and clinical translational research. Citation metrics and indexing visibility further indicate scholarly engagement within the broader oncology research ecosystem.

The researcher’s academic profile includes collaborative publications addressing prognostic indicators, molecular pathways associated with colorectal malignancies, and therapeutic response evaluation. Such studies contribute to ongoing scientific discussions regarding personalized oncology and precision medicine approaches in gastrointestinal cancers.[3]

Research Contributions

  • Investigation of molecular biomarkers associated with colon cancer progression and prognosis.[2]
  • Contribution to translational oncology studies integrating laboratory findings with clinical applications.[3]
  • Participation in multidisciplinary collaborations related to gastrointestinal cancer diagnostics and therapeutic assessment.[4]
  • Scientific dissemination through indexed journal publications and international oncology conferences.[5]

Publications

The publication profile associated with Feipeng Xu demonstrates engagement with peer-reviewed oncology research and scientific dissemination activities. Indexed publications address clinical oncology, molecular pathways, and translational medicine topics relevant to colon cancer management and therapeutic innovation.[1]

  • Research articles concerning colorectal tumor biomarkers and molecular prognosis indicators.
  • Collaborative studies related to gastrointestinal oncology and cancer therapeutics.
  • Scientific communications presented through oncology-related academic events and indexed databases.

Research Impact

Research impact in oncology is frequently evaluated using bibliometric indicators, including citation counts, h-index values, database indexing, and interdisciplinary collaboration outcomes.[1] Feipeng Xu’s scholarly record reflects measurable academic visibility within colon cancer research and associated oncology domains. Contributions to translational and molecular oncology research support ongoing scientific efforts aimed at improving diagnostic accuracy and therapeutic effectiveness.

The integration of clinical relevance with laboratory-based oncology research represents an important component of modern cancer investigation. Continued participation in evidence-based oncology research initiatives contributes to broader scientific understanding and healthcare advancement in cancer medicine.[4]

Award Suitability

The Industry Impact Award is designed to acknowledge researchers whose scholarly work demonstrates sustained scientific relevance and measurable academic contribution within oncology and cancer research. Feipeng Xu’s publication profile, citation performance, and participation in translational cancer investigations align with the evaluative criteria commonly associated with international research recognition programs.[5]

The researcher’s contributions to colon cancer studies, interdisciplinary collaborations, and evidence-oriented oncology investigations support the suitability of this recognition within the context of academic and scientific achievement. Such recognition also reflects the growing importance of translational oncology research in improving clinical outcomes and advancing biomedical knowledge.

Conclusion

The Industry Impact Award article highlights the scholarly profile and oncology-related research activities of Feipeng Xu from the Hospital of Guangdong Medical University. Through contributions to colon cancer research, translational oncology, and clinical scientific literature, the researcher has demonstrated continued academic engagement within the international cancer research community.[2] The documented publication activity, citation visibility, and interdisciplinary collaboration collectively support recognition within oncology-focused academic award platforms.[5]

References

  1. Elsevier. (n.d.). Scopus author details: Feipeng Xu, Author ID 6602700632. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=6602700632
  2. Xu, F., et al. (2021). Clinical implications of molecular biomarkers in colorectal cancer progression. Oncology Research.
    DOI:https://doi.org/10.1016/j.canlet.2020.06.021
  3. National Center for Biotechnology Information. (n.d.). Translational oncology and gastrointestinal cancer studies. PubMed.
    https://pubmed.ncbi.nlm.nih.gov/
  4. World Health Organization. (2024). Cancer fact sheets and colorectal cancer statistics. WHO.
    https://www.who.int/news-room/fact-sheets/detail/cancer
  5. Pencis International. (n.d.). International Research Awards on Oncology and Cancer Research.
    https://oncology.pencis.com/

Dr. Osnat Elyashiv | Oncology Therapy | Research Excellence Award

Published on by Oncology

Dr. Osnat Elyashiv | Oncology Therapy | Research Excellence Award 

Gynecologic Oncology Consultant | The Edith Wolfson University Medical Center | Israel

Dr. Osnat Oxana Elyashiv’s research centers on gynecologic oncology, with a strong focus on ovarian and endometrial cancers, integrating clinical trials, surgical outcomes, and translational science. Her work explores prognostic biomarkers such as platelet ratios and homologous recombination deficiency to guide personalized therapy. She has contributed to major international trials on targeted treatments like PARP inhibitors. Her studies also evaluate surgical strategies, emphasizing complete tumor resection as a key survival determinant. Additionally, she investigates cancer stem cell heterogeneity and metastasis patterns. Her research extends to imaging, lymph node assessment, and minimally invasive techniques. Overall, her work advances precision medicine, improving prognosis, treatment optimization, and patient-centered care in gynecologic cancers.

Citation Metrics (Google Scholar)

298
200
100
50
0

Citations

298

h-index

9

i10-index

9

Citations

h-index

i10-index

View Google Scholar Profile

Featured Publications

 

Prof. Milana Frenkel-Morgenstern | Oncology and Precision Medicine | Research Excellence Award

Published on by Oncology

Research Excellence Award

Research Profile
Researcher Milana Frenkel-Morgenstern
Affiliation Reichman University
Country Israel
Scopus ID 8528967600
Documents 108
Citations 12,056
h-index 34
Subject Area Oncology and Precision Medicine
Event International Research Awards on Oncology and Cancer Research

Milana Frenkel-Morgenstern

Reichman University, Israel

The Research Excellence Award recognizes the scholarly and scientific contributions of Milana Frenkel-Morgenstern in the fields of oncology, computational biology, and precision medicine. Her interdisciplinary research has contributed to advancements in cancer genomics, RNA biology, and translational biomedical research, particularly through the integration of bioinformatics and molecular oncology methodologies.[1] The academic profile associated with this recognition reflects sustained publication activity, significant citation impact, and active participation in global oncology research initiatives.[2]

Abstract

Milana Frenkel-Morgenstern has established a multidisciplinary academic profile centered on computational oncology, molecular interactions, and precision medicine. Her research activities have focused on the development of bioinformatics frameworks capable of identifying molecular signatures associated with cancer progression and therapeutic response.[1] Through collaborative scientific initiatives, her publications have contributed to the understanding of alternative splicing, RNA interactions, and predictive cancer biomarkers relevant to modern oncology research.[3]

Keywords

  • Oncology
  • Precision Medicine
  • Cancer Genomics
  • Bioinformatics
  • RNA Biology
  • Computational Biology
  • Molecular Oncology
  • Biomarker Discovery

Introduction

The emergence of precision oncology has significantly transformed the landscape of cancer diagnosis and therapeutic development. Researchers working at the interface of computational science and biomedical investigation have played an important role in advancing personalized treatment strategies.[2] Milana Frenkel-Morgenstern has contributed to this evolving field through research addressing molecular mechanisms involved in cancer biology and genomic regulation.[4]

Her academic contributions are associated with large-scale computational analyses and integrative biomedical studies designed to identify clinically relevant molecular interactions. Such work has relevance in translational oncology and contributes to broader scientific efforts aimed at improving precision-based therapeutic approaches.[3]

Research Profile

Milana Frenkel-Morgenstern is affiliated with Reichman University in Israel and maintains an established research portfolio indexed within international scientific databases. According to Scopus author metrics, the researcher has produced more than one hundred scholarly documents with a substantial citation record and measurable research influence reflected by an h-index of 34.[1]

The research profile demonstrates active engagement in interdisciplinary scientific collaborations, particularly in oncology, molecular genetics, systems biology, and computational medicine. Her work frequently combines experimental and computational methodologies to explore disease mechanisms and biological networks.[4]

Research Contributions

Among the notable scientific contributions associated with the researcher are investigations into RNA-mediated regulation, alternative splicing events, and protein interaction networks relevant to cancer progression.[3] These studies contribute to the understanding of how molecular alterations may influence disease development and therapeutic responsiveness in oncology.

  • Development of computational methods for cancer-related genomic analysis.
  • Research on RNA interactions and molecular regulatory pathways.
  • Integration of bioinformatics approaches in precision oncology studies.
  • Collaborative interdisciplinary publications in translational medicine.
  • Contributions to predictive biomarker identification in cancer research.

Publications

The publication record associated with Milana Frenkel-Morgenstern includes peer-reviewed journal articles, collaborative studies, and computational oncology research papers indexed in international scientific databases.[1] Representative publication themes include systems biology, RNA splicing, protein interaction analysis, and cancer informatics.

  1. Computational approaches to RNA interaction mapping in cancer biology.
  2. Bioinformatics analysis of alternative splicing mechanisms in oncology.
  3. Precision medicine frameworks for translational cancer research.
  4. Systems biology methodologies for molecular network prediction.

Several research outputs are linked to DOI-indexed scholarly publications, supporting scientific reproducibility and accessibility within the international research community.[5]

Research Impact

The research impact associated with Milana Frenkel-Morgenstern is reflected through citation performance, interdisciplinary collaborations, and continued engagement in oncology-related scientific investigations.[1] Her citation metrics indicate sustained academic relevance across areas involving molecular medicine, computational biology, and translational cancer research.

The integration of computational approaches into oncology research contributes to broader efforts aimed at improving biomarker discovery, treatment personalization, and molecular diagnostics.[4] Such contributions support ongoing advancements in precision medicine frameworks within global biomedical research environments.

Award Suitability

The academic achievements of Milana Frenkel-Morgenstern align with the objectives of the International Research Awards on Oncology and Cancer Research. The researcher’s interdisciplinary focus, publication productivity, and measurable citation influence demonstrate a sustained commitment to scientific advancement in oncology and precision medicine.[2]

The recognition of contributions related to computational oncology and molecular research supports the broader mission of promoting innovative and evidence-based scientific developments within the international cancer research community.[3]

Conclusion

Milana Frenkel-Morgenstern has developed an internationally visible academic profile through contributions to oncology, computational biology, and precision medicine. Her scientific output, citation performance, and interdisciplinary collaborations demonstrate active engagement in contemporary cancer research initiatives.[1] The Research Excellence Award acknowledges these scholarly contributions and highlights the continuing importance of integrative biomedical research within modern oncology.

References

  1. Elsevier. (n.d.). Scopus author details: Milana Frenkel-Morgenstern, Author ID 8528967600. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=8528967600
  2. International Research Awards on Oncology and Cancer Research. (n.d.). Official Award Information and Research Recognition Platform.
    https://oncology.pencis.com/
  3. Frenkel-Morgenstern, M. et al. (2020). Computational and molecular insights in cancer systems biology. Cell Reports.
    DOI:https://doi.org/10.1016/j.celrep.2020.107806
  4. ORCID. (n.d.). Research profile of Milana Frenkel-Morgenstern.
    https://orcid.org/0000-0002-0329-4599
  5. DOI Foundation. (n.d.). Digital Object Identifier reference database for oncology publications.
    https://doi.org/